Sign In
Buy TIL
$7.12
-0.0200 (-0.280%)
At Close: Jul 31, 2026
Instil Bio to Present at Upcoming Investor Conferences in November
08:05am, Monday, 08'th Nov 2021
DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapi
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
07:00am, Monday, 13'th Sep 2021
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma
At a Recent Cancer Research Conference, Instil Bio Stole the Show
08:45am, Thursday, 29'th Apr 2021
The clinical-stage cell therapy company reported impressive response rates for its candidate treatment against metastatic melanoma.
67% overall response rate and 19% complete response rate in 21 patients
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
05:00pm, Tuesday, 23'rd Mar 2021
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL thera
US IPO Weekly Recap: The IPO Market Heats Up In An 11 IPO Week
11:43am, Sunday, 21'st Mar 2021
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings.
TIL Stock Price Increased 32.2% In Market Debut
08:17am, Saturday, 20'th Mar 2021
The stock price of Instil Bio Inc (NASDAQ: TIL) increased by 32.2% in its market debut. These are the details.
Instil Bio Announces Pricing of Upsized Initial Public Offering
08:26pm, Thursday, 18'th Mar 2021
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL thera
